Patent ID: 7741316
Filing Date: 2010-06-22
Classification: A61P,C04B,C07D

Abstract:
1. A method of antagonizing the cannabinoid (CB1) receptor wherein a disease treatable by said antagonizing activity is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and schizophrenia, this method comprising administering to a patient in need of said antagonization an effective amount of a compound of formula in which R represents a radical selected from CR or R R aromatic radical selected from phenyl, naphthyl and indenyl, these aromatic radicals being unsubstituted or substituted with one or more radicals selected from halogen, alkyl, alkoxy, formyl, hydroxyl, trifluoromethyl, trifluoromethoxy, —CO-alk, R R R R R R R R R R R R R R R or, alternatively, R —NR R alternatively, R R alternatively, R R alternatively, R R n is equal to 1, 2 or 3, R alternatively, R R alternatively, R Ar represents a phenyl or naphthyl radical optionally substituted with one or more substituents selected from halogen, alkyl, alkoxy, —CO-alk, cyano, —COOH, —COOalk, —CONR Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more halogen, alkyl, alkoxy, alkoxycarbonyl, —CONR the alkyl, alkylene and alkoxy radicals are in the form of a straight or branched chain and contain 1 to 6 carbon atoms, the cycloalkyl radicals contain 3 to 10 carbon atoms and the heterocycloalkyl and heterocyclenyl radicals contain 3 to 10 carbon atoms, their optical isomers and their salts with an inorganic or organic acid.